Splenic Hemangioma as a Potential Pitfall on PSMA-Targeted 18F-DCFPyL PET/CT. (March 2019)

• Record Type: Journal Article
• Authors: Chaussé, Guillaume; Laufer, Jerome; Abikhzer, Gad; Probst, Stephan
• Is Part Of: Clinical nuclear medicine. Volume 44:Number 3(2019)
• Publication Date: 2019-03
• Subjects: DCFPyL -- PMSA -- PET -- CT -- MRI -- spleen -- hemangioma; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000002428
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: A 69-year-old man with biochemical recurrence after radical prostatectomy underwent 6 months of androgen deprivation therapy. Upon discontinuation of androgen deprivation therapy, serum prostate-specific antigen rose again to 0.69 ng/mL, and 18 F-DCFPyL PET/CT was performed to identify the site of recurrence. However, only an intense focus of uptake in the spleen could be found. Subsequent contrast-enhanced MRI findings were pathognomonic for splenic hemangioma.